Zacks Investment Research upgraded shares of China Biologic Products Inc. (NASDAQ:CBPO) from a hold rating to a buy rating in a research note released on Monday morning. Zacks Investment Research currently has $138.00 price target on the biopharmaceutical company’s stock.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

A number of other research firms have also commented on CBPO. Jefferies Group lifted their price target on shares of China Biologic Products from $136.00 to $155.00 and gave the company a buy rating in a research report on Friday, August 5th. Credit Suisse Group AG raised shares of China Biologic Products from a neutral rating to an outperform rating in a research report on Tuesday, July 5th.

China Biologic Products (NASDAQ:CBPO) traded down 2.71% on Monday, hitting $119.84. 55,769 shares of the stock were exchanged. The company’s 50 day moving average is $119.27 and its 200 day moving average is $117.24. The stock has a market cap of $3.22 billion, a PE ratio of 34.56 and a beta of 1.55. China Biologic Products has a 1-year low of $95.70 and a 1-year high of $144.29.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.10. China Biologic Products had a net margin of 29.66% and a return on equity of 19.65%. The company had revenue of $91.40 million for the quarter, compared to analyst estimates of $87.60 million. During the same quarter last year, the firm posted $1.06 earnings per share. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, equities research analysts expect that China Biologic Products will post $4.33 earnings per share for the current year.

In other news, Director Wenfang Liu sold 2,900 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $360,528.00. Following the sale, the director now owns 3,383 shares in the company, valued at approximately $420,574.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Zhijing Cbpo Liu sold 1,968 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $124.32, for a total transaction of $244,661.76. The disclosure for this sale can be found here. Company insiders own 2.68% of the company’s stock.

Large investors have recently modified their holdings of the stock. ProShare Advisors LLC increased its stake in shares of China Biologic Products by 0.6% in the second quarter. ProShare Advisors LLC now owns 19,793 shares of the biopharmaceutical company’s stock valued at $2,104,000 after buying an additional 109 shares in the last quarter. Legal & General Group Plc increased its stake in shares of China Biologic Products by 23.5% in the second quarter. Legal & General Group Plc now owns 2,101 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 400 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of China Biologic Products by 9.9% in the first quarter. Geode Capital Management LLC now owns 10,512 shares of the biopharmaceutical company’s stock valued at $1,203,000 after buying an additional 950 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of China Biologic Products by 3.3% in the second quarter. GSA Capital Partners LLP now owns 41,815 shares of the biopharmaceutical company’s stock valued at $4,446,000 after buying an additional 1,320 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of China Biologic Products by 3,357.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,383 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,343 shares in the last quarter. Institutional investors own 71.71% of the company’s stock.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.